Wei‐Pang Chung

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung et al. · The Lancet · 2022 · 642 citations · Full text

Medicine, Oncology, Pharmacology +16

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2024 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Peter Schmid, Seock‐Ah Im, Anne Armstrong et al. · Journal of Clinical Oncology · 2021 · 110 citations

Medicine, Oncology, Pharmacology +17

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim et al. · Journal of Clinical Oncology · 2024 · 79 citations · Full text

Medicine, Oncology, Pharmacology +17